Lenz Therapeutics, INC 8-K filings

Lenz Therapeutics reported $5.5 million in Q2 2026 revenue, driven by VIZZ sales and license agreements, alongside the launch of a new telehealth channel.

Lenz Therapeutics reports a director's resignation and a subsequent adjustment to the Board size and Audit Committee composition.

LENZ Therapeutics shareholders re-elected Class II directors and ratified the appointment of Ernst & Young LLP as the company's independent auditor.

LENZ Therapeutics announced its fourth quarter and full year 2025 financial results, highlighting a successful initial launch of VIZZ for presbyopia with $1.6 million in net product revenue.

LENZ Therapeutics announced preliminary unaudited Q4 2025 financial results, reporting $1.6 million in VIZZ net product revenue and over 20,000 prescriptions filled.

LENZ Therapeutics, Inc. reported an adverse event of a retinal tear in a patient using VIZZ, noting pre-existing risk factors and an uncertain causal link.

LENZ Therapeutics announced its third quarter 2025 financial results, highlighting the successful commercial launch of VIZZ for presbyopia and a strong cash position.

LENZ Therapeutics, Inc. announced the sale of 1,748,634 shares of common stock to a single investor, generating approximately $80 million in gross proceeds.

LENZ Therapeutics announces the commercial availability of VIZZ, the first and only FDA-approved aceclidine-based eye drop for presbyopia, in the United States.

LENZ Therapeutics announced the US Food and Drug Administration (FDA) approved VIZZ (aceclidine ophthalmic solution) 1.44%, the first and only aceclidine-based eye drop for the treatment of presbyopia in adults.

LENZ Therapeutics announced its second quarter 2025 financial results, highlighting the LNZ100 NDA remains on track for an August 8, 2025 PDUFA date and significant progress in global commercialization efforts.

LENZ Therapeutics, Inc. announced the successful election of Class III and Class I directors and the ratification of Ernst & Young LLP as its independent registered public accounting firm at its 2025 annual meeting of stockholders.

LENZ Therapeutics announces its Q1 2025 financial results, highlighting progress on its NDA for LNZ100 and a strong cash position.

Lenz Therapeutics reports approximately $194 million in cash, cash equivalents, and marketable securities as of March 31, 2025, in anticipation of the potential approval and launch of LNZ100.

LENZ Therapeutics has entered into a sales agreement with TD Cowen to sell up to $150 million of its common stock through an at-the-market offering program.

LENZ Therapeutics reports financial results for 2024 and highlights progress towards the potential approval and launch of LNZ100 for presbyopia, with a PDUFA target action date of August 8, 2025.

LENZ Therapeutics reported positive Phase 3 results for their presbyopia treatment, LNZ100, and announced the FDA's acceptance of their New Drug Application with a target action date of August 8, 2025.

LENZ Therapeutics and Corxel Pharmaceuticals reported successful topline results from a Phase 3 trial in China for their LNZ100 eye drop, showing significant improvement in near vision for patients with presbyopia.

LENZ Therapeutics has submitted a New Drug Application to the FDA for its LNZ100 eye drop for presbyopia, following positive Phase 3 trial results and a $30 million private placement.

LENZ Therapeutics has submitted a New Drug Application to the U.S. Food and Drug Administration for its LNZ100 eye drop, aimed at treating presbyopia.

LENZ Therapeutics has entered into a stock purchase agreement with Ridgeback Capital Investments for a $30 million private placement to support the development and commercialization of its presbyopia treatment, LNZ100.

LENZ Therapeutics reported positive topline data from its Phase 3 CLARITY study for presbyopia, selected LNZ100 as its lead candidate, and anticipates a New Drug Application submission in mid-2024.

LENZ Therapeutics' LNZ100 eye drop demonstrated strong efficacy and safety in Phase 3 trials for presbyopia, with a New Drug Application submission planned for mid-2024.

LENZ Therapeutics has finalized its merger with Graphite Bio, debuting on Nasdaq under the ticker symbol LENZ, and is advancing its late-stage clinical assets for the treatment of presbyopia.

Graphite Bio will enact a 1-for-7 reverse stock split and change its name to Lenz Therapeutics on March 21, 2024, in preparation for its merger with Lenz Therapeutics.

Graphite Bio stockholders have approved the merger with LENZ Therapeutics, along with related proposals including a reverse stock split and a name change to LENZ Therapeutics, Inc.

Graphite Bio has declared a special cash dividend of approximately $1.03 per share for its stockholders, contingent on the closing of its merger with Lenz Therapeutics.

Graphite Bio provides supplemental disclosures to its proxy statement/prospectus in response to litigation and demand letters related to its merger with Lenz Therapeutics.